CACNA2D1 blockers(Voltage-gated calcium channel alpha2/delta subunit 1 blockers), CACNA2D2 blockers(Voltage-gated calcium channel alpha2/delta subunit 2 blockers)

Therapeutic Areas

Nervous System DiseasesEndocrinology and Metabolic Disease

Active Indication

Diabetic peripheral neuropathic painNeuralgia

Inactive Indication

Chronic Kidney DiseasesFibromyalgiaNeuralgia, Postherpetic

Originator Organization

Daiichi Sankyo Co., Ltd.

Active Organization

Daiichi Sankyo Co., Ltd.

Daiichi Sankyo, Inc.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

JP (08 Jan 2019),

Neuralgia

RegulationSpecial Review Project (CN)

Structure

Molecular FormulaC18H25NO5S

InChIKeyOKJXJRVWXYRSAN-TXULWXBWSA-N

CAS Registry1138245-21-2

View All Structures (2)

Clinical Trials associated with Mirogabalin Besilate

CTR20243712 / Active, not recruitingNot Applicable

苯磺酸美洛加巴林片餐后人体生物等效性试验

[Translation] Postprandial bioequivalence study of melogabalin besylate tablets in healthy volunteers

主要目的：以健康受试者为试验对象，采用开放、随机、两周期、双交叉试验设计，考察健康受试者餐后单次口服由江苏万禾制药有限公司生产（南京万融健诚医药科技有限公司持证）的苯磺酸美洛加巴林片（受试制剂，规格：5mg）与第一三共株式会社生产的苯磺酸美洛加巴林片（参比制剂， TARLIGE ®，规格：5mg）后美洛加巴林的体内经时过程，估算其相关药代动力学参数及相对生物利用度，评价其餐后状态下的生物等效性，为受试制剂的生产注册申请提供依据。次要目的：评价苯磺酸美洛加巴林片受试制剂和参比制剂（商品名：TARLIGE®）在健康受试者中的安全性。

[Translation]

Main purpose: To use healthy subjects as test subjects, adopt an open, randomized, two-period, double-crossover design, to investigate the in vivo time course of melogabalin after a single oral administration of melogabalin besylate tablets (test preparation, specification: 5 mg) produced by Jiangsu Wanhe Pharmaceutical Co., Ltd. (certified by Nanjing Wanrong Jiancheng Pharmaceutical Technology Co., Ltd.) and melogabalin besylate tablets (reference preparation, TARLIGE ®, specification: 5 mg) produced by Daiichi Sankyo Co., Ltd. after meals, estimate their relevant pharmacokinetic parameters and relative bioavailability, evaluate their bioequivalence in the postprandial state, and provide a basis for the production registration application of the test preparation. Secondary purpose: To evaluate the safety of the test preparation and reference preparation of melogabalin besylate tablets (trade name: TARLIGE®) in healthy subjects.

Start Date14 Nov 2024

Sponsor / Collaborator

Nanjing Wanrong Jiancheng Pharmaceutical Technology Co., Ltd.

CTR20243713 / Active, not recruitingNot Applicable

苯磺酸美洛加巴林片空腹人体生物等效性试验

[Translation] Bioequivalence study of melogabalin besylate tablets in fasting volunteers

主要目的：以健康受试者为试验对象，采用开放、随机、两周期、双交叉试验设计，考察健康受试者空腹单次口服由江苏万禾制药有限公司生产（南京万融健诚医药科技有限公司持证）的苯磺酸美洛加巴林片（受试制剂，规格：5mg）与第一三共株式会社生产的苯磺酸美洛加巴林片（参比制剂， TARLIGE ®，规格：5mg）后美洛加巴林的体内经时过程，估算其相关药代动力学参数及相对生物利用度，评价其空腹状态下的生物等效性，为受试制剂的生产注册申请提供依据。次要目的：评价苯磺酸美洛加巴林片受试制剂和参比制剂（商品名：TARLIGE®）在健康受试者中的安全性。

[Translation]

Main purpose: Using healthy subjects as test subjects, an open, randomized, two-period, double-crossover design was used to investigate the in vivo time course of melogabalin after a single oral administration of melogabalin besylate tablets (test preparation, specification: 5 mg) produced by Jiangsu Wanhe Pharmaceutical Co., Ltd. (certified by Nanjing Wanrong Jiancheng Pharmaceutical Technology Co., Ltd.) and melogabalin besylate tablets (reference preparation, TARLIGE ®, specification: 5 mg) produced by Daiichi Sankyo Co., Ltd. on an empty stomach, to estimate their relevant pharmacokinetic parameters and relative bioavailability, to evaluate their bioequivalence under fasting conditions, and to provide a basis for the production registration application of the test preparation. Secondary purpose: To evaluate the safety of the test preparation and reference preparation of melogabalin besylate tablets (trade name: TARLIGE®) in healthy subjects.

Start Date14 Oct 2024

Sponsor / Collaborator

Nanjing Wanrong Jiancheng Pharmaceutical Technology Co., Ltd.

CTR20242717 / Active, not recruitingNot Applicable

评估受试制剂苯磺酸美洛加巴林片与参比制剂苯磺酸美洛加巴林片（TARLIGE®）作用于健康成年受试者的单中心、开放、随机、单剂量、交叉生物等效性研究

[Translation] A single-center, open-label, randomized, single-dose, crossover bioequivalence study to evaluate the test product, melogabalin besylate tablets, and the reference product, melogabalin besylate tablets (TARLIGE®) in healthy adult subjects

研究空腹/餐后状态下单次口服受试制剂苯磺酸美洛加巴林片与参比制剂苯磺酸美洛加巴林片（TARLIGE®）在健康成年受试者体内的药代动力学，评价空腹/餐后状态下口服两种制剂的生物等效性和安全性。

[Translation]

To investigate the pharmacokinetics of a single oral dose of the test formulation, melogabalin besylate tablets, and the reference formulation, melogabalin besylate tablets (TARLIGE®), in healthy adult subjects in the fasting/fed state, and to evaluate the bioequivalence and safety of the two formulations in the fasting/fed state.

Start Date25 Aug 2024

Sponsor / Collaborator

Qilu Pharmaceutica Hainanco Ltd.

100 Clinical Results associated with Mirogabalin Besilate

100 Translational Medicine associated with Mirogabalin Besilate

100 Patents (Medical) associated with Mirogabalin Besilate

120

Literatures (Medical) associated with Mirogabalin Besilate

01 Nov 2024·Clinical Case Reports

Duloxetine‐induced syndrome of inappropriate antidiuretic hormone secretion in a patient with neuropathic pain

Article

Author: Momo, Kenji ; Takahashi, Nobuyuki ; Mori, Yukiko ; Tanaka, Hironori ; Murakami, Hidetomo

Key Clinical MessageSyndrome of inappropriate antidiuretic hormone secretion (SIADH) induces hyponatremia accompanied by uric acid reduction. We report a case of a patient with small‐cell lung cancer who developed SIADH with hypouricemia after duloxetine treatment and discuss the potential underlying mechanisms. SIADH and hypouricemia improved after duloxetine was switched to mirogabalin.

01 Oct 2024·Pain and Therapy

Usefulness of Mirogabalin in Central Neuropathic Pain After Stroke: Post Hoc Analysis of a Phase 3 Study by Stroke Type and Location

Article

Author: Katayama, Yoichi ; Ushida, Takahiro ; Kuroha, Masanori ; Sakoda, Hiroshi ; Hosomi, Koichi ; Kikumori, Kunika

INTRODUCTIONCentral post-stroke pain (CPSP) is a common type of central neuropathic pain (CNeP) that can occur following the onset of stroke. The oral gabapentinoid mirogabalin besylate (mirogabalin) is a selective α₂δ ligand that is effective for the treatment of CNeP, including CPSP. However, it is unknown whether the analgesic effect of mirogabalin on CPSP varies in patients with different background factors.METHODSThis was a post hoc subgroup analysis of a multinational, open-label, long-term phase 3 study of mirogabalin for the treatment of CNeP conducted between March 2019 and December 2020. Data from patients with CPSP were stratified by type of stroke (ischemic or hemorrhagic), stroke location (thalamus, putamen, brainstem, or other), presence/absence of motor weakness, median time since stroke (≥ 59 or < 59 months), and median duration of CPSP (≥ 55.5 or < 55.5 months). Efficacy was assessed with the short-form McGill Pain Questionnaire (SF-MPQ), and treatment-emergent adverse events (TEAEs) and adverse drug reactions (ADRs) were recorded.RESULTSThis subanalysis included all 94 patients with CPSP from the phase 3 study; all were Japanese, and the mean age was 65.3 years. The least squares mean change [95% confidence interval] in SF-MPQ visual analog scale (VAS) score from baseline at week 52 (last observation carried forward) was - 17.0 [- 22.1, - 11.9] mm. Among the subgroups, least squares mean changes in SF-MPQ VAS scores were not different. Most TEAEs were mild or moderate; severe TEAEs occurred in six patients (6.4%). Somnolence (25.5%), peripheral edema (13.8%), dizziness (11.7%), and weight gain (6.4%) were the most common ADRs, and the types and frequencies of ADRs were similar among subgroups.CONCLUSIONMirogabalin was generally effective and well tolerated in patients with CPSP, regardless of background factors such as stroke type or location, presence/absence of motor weakness, time since stroke, and duration of CPSP.TRIAL REGISTRATIONTrial registration number NCT03901352.

01 Sep 2024·Journal of Endodontics

Mirogabalin as a Therapeutic Option for Neuropathic Pain Emerging Post-endodontic Treatment: A Two-Case Report

Article

Author: Takeichi, Osamu ; Ohara, Kinuyo ; Hayashi, Makoto ; Noma, Noboru ; Shimizu, Kohei ; Yasukawa, Takuya

INTRODUCTIONOcclusal and percussion pain may manifest occasionally following endodontic treatment, influencing retreatment decisions. Two cases of periapical neuropathic pain, classified as post-traumatic trigeminal neuropathic pain according to the International Classification of Orofacial Pain, are presented. Although mirogabalin is effective in managing neuropathic pain, there is a lack of clinical reports on its use for occasional post-traumatic trigeminal neuropathic pain after endodontic treatment. These cases highlight clinical symptoms and successful treatment with mirogabalin for post-traumatic trigeminal neuropathic pain after endodontic treatment, providing clinicians a "take-away" lesson for improving patient condition.METHODSThe patients, referred by their primary dentist due to postendodontic abnormal pain, found no relief with antibiotics or nonsteroidal anti-inflammatory drugs. Although no findings including swelling or periapical radiolucency were observed around the tooth, they experienced occlusal and percussion pain. Local anesthetic testing showed that the pain originated from the peripheral area around the tooth rather than from central sensitization. Dental radiography and cone-beam computed tomography revealed no abnormal findings. Root canal retreatment was performed by a specialist in endodontic treatment. Although endodontic retreatment drastically decreased visual analog scale pain score, pain persisted. Based on the International Classification of Orofacial Pain criteria, diseases other than post-traumatic trigeminal neuropathic pain were excluded. Mirogabalin (10 mg/d) was prescribed once daily before bedtime.RESULTSVisual analog scale scores gradually and drastically decreased 2 weeks after mirogabalin therapy. Several months later, no recurrence of postendodontic pain was observed after tapering off and discontinuing mirogabalin.CONCLUSIONSThese findings suggest the possibility of a new treatment method for post-traumatic trigeminal neuropathic pain after endodontic treatment.

News (Medical) associated with Mirogabalin Besilate

28 Aug 2024

·www.prnewswire.com

Peripheral Neuropathic Pain Market to Exhibit Growth at a CAGR of 4.1% by 2034 | DelveInsight

The increasing cases of peripheral neuropathic pain, rise in screening for diabetic neuropathic pain among diabetics, increase in the geriatric population, and launch of new approved drugs, among other reasons are likely to fuel the growth of the peripheral neuropathic pain market size during the forecast period (2024–2034). LAS VEGAS, Aug. 28, 2024 /PRNewswire/ --DelveInsight's Peripheral Neuropathic Pain Market Insights report includes a comprehensive understanding of current treatment practices, peripheral neuropathic pain emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan]. Key Takeaways from the Peripheral Neuropathic Pain Market Report According to DelveInsight's analysis, the market size for peripheral neuropathic pain was found to be ~ USD 12 billion in the 7MM in 2023. The United States accounts for the largest market size of PNP in comparison to EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan. The total cases of peripheral neuropathic pain in the 7MM were approximately 60 million cases in 2023, which are expected to increase during the study period (2020–2034). Leading peripheral neuropathic pain companies such as Lexicon Pharmaceuticals, Merz Therapeutics, Apurano Pharmaceuticals, Vertex Pharmaceuticals, WEX Pharmaceuticals, Scilex Holding Company, and others are developing novel peripheral neuropathic pain drugs that can be available in the peripheral neuropathic pain market in the coming years. The promising peripheral neuropathic pain therapies in the pipeline include LX9211, XEOMIN (incobotulinumtoxinA), Adezunap (AP707), Suzetrigine (VX-548), HALNEURON (Tetrodotoxin or TTX), SEMDEXA (SP-102), and others. Compared to all the emerging therapies, LX9211 and SEMDEXA are expected to become the market leader, having a major influence on the peripheral neuropathic pain market of the 7MM by 2034. In November 2023, Lexicon Pharmaceuticals announced that it has enrolled the first patient in PROGRESS (A Phase IIb, dose-ranging, randomized, double-blind, placebo-controlled, parallel-group, multicenter study with an open-label extension in patients with diabetic peripheral neuropathic pain) studying LX9211. Discover which therapies are expected to grab the major peripheral neuropathic pain market share @ Peripheral Neuropathic Pain Market Report Peripheral Neuropathic Pain Overview Peripheral neuropathies refer to conditions affecting peripheral nerve cells and fibers, arising from a variety of underlying causes. These nerves include the cranial nerves, spinal nerve roots and ganglia, nerve trunks and divisions, and the autonomic nervous system nerves. Peripheral neuropathies can be classified in several ways, such as mononeuropathies, multifocal neuropathies, and polyneuropathies. Mononeuropathy involves damage to a single nerve, while multiple mononeuropathy affects two or more nerves in different locations. Polyneuropathy typically impacts many or most nerves. The diversity of symptoms associated with peripheral neuropathy allows for the identification of distinct clinical phenotypes, which is important for guiding the diagnostic process. Nerve conduction studies are crucial for determining the phenotype and assessing severity. Additional diagnostic tools, such as laboratory tests, genetic testing, cerebrospinal fluid examination, nerve imaging, and nerve biopsy, may be useful in specific clinical situations. Peripheral Neuropathic Pain Epidemiology Segmentation The peripheral neuropathic pain epidemiology section provides insights into the historical and current peripheral neuropathic pain patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders. The peripheral neuropathic pain market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Cases of PNP Type-specific Cases of PNP Treated Cases of PNP Peripheral Neuropathic Pain Treatment Market The treatment of peripheral neuropathic pain depends on the underlying cause and the severity of symptoms. Initial management typically involves conservative measures, including medications such as NSAIDs, acetaminophen, and, in more severe cases, opioids. For radicular symptoms, neuroleptic agents may be used, and systemic steroids are sometimes prescribed for acute low back pain. Nonpharmacological treatments like physical therapy, acupuncture, chiropractic manipulation, and traction are also employed, though their effectiveness is debated. Interventional procedures, such as epidural steroid injections and percutaneous disc decompression, are commonly performed, while surgical options like decompression and spinal fusion are considered for cases that do not respond to other treatments. Pain management for PNP also includes the use of drugs such as NSAIDs, anticonvulsants, and antidepressants, with specific medications like QUTENZA, NUCYNTA ER, and TARLIGE approved for certain patient groups. TARLIGE (mirogabalin besylate) is an oral gabapentinoid developed by Daiichi Sankyo to treat peripheral neuropathic pain (PNP), including diabetic PNP and postherpetic neuralgia. In January 2019, Daiichi Sankyo announced that TARLIGE received approval for marketing in Japan for PNP treatment, offering patients in Japan a new therapeutic option for managing PNP. NUCYNTA ER (tapentadol) is an opioid agonist available as an extended-release film-coated tablet for oral use. It is prescribed for managing neuropathic pain related to diabetic peripheral neuropathy (DPN). In August 2012, the US FDA approved a sNDA for NUCYNTA ER, allowing it to be used as an oral analgesic taken twice daily to manage neuropathic pain in adults with DPN when ongoing, around-the-clock opioid treatment is required for a prolonged duration. The QUTENZA (capsaicin) 8% topical system delivers capsaicin through a localized dermal application. Capsaicin acts as an agonist for the TRPV1 receptor. In July 2020, Grünenthal's US subsidiary, Averitas Pharma, obtained FDA approval for the QUTENZA 8% patch to treat neuropathic pain related to diabetic peripheral neuropathy in the feet of adults. To know more about peripheral neuropathic pain treatment guidelines, visit @ Peripheral Neuropathic Pain Management Peripheral Neuropathic Pain Pipeline Therapies and Key Companies LX9211: Lexicon Pharmaceuticals XEOMIN (IncobotulinumtoxinA): Merz Therapeutics Adezunap (AP707): Apurano Pharmaceuticals Suzetrigine (VX-548): Vertex Pharmaceuticals HALNEURON (Tetrodotoxin or TTX): WEX Pharmaceuticals SEMDEXA (SP-102): Scilex Holding Company Discover more about peripheral neuropathic pain drugs in development @ Peripheral Neuropathic Pain Clinical Trials Peripheral Neuropathic Pain Market Dynamics The peripheral neuropathic pain market dynamics are expected to change in the coming years. Emerging disease-modifying therapies for diabetic neuropathy, CIPN, and LSR are gaining attention due to the growing prevalence of cancer, increased chemotherapy usage, and the large patient pool in need of pain management. The lack of disease-modifying treatment options in the current landscape, which relies solely on symptomatic relief, highlights the market potential for these therapies. Recent developmental activities targeting novel pathways, such as adapter-associated kinase 1 (AAK1) and the Nav1.8 voltage-gated sodium channel, aim to provide opioid-free pain relief, which could lead to a high uptake and the ability to charge a premium price. Furthermore, potential therapies are being investigated for the treatment of peripheral neuropathic pain, and it is safe to predict that the treatment space will significantly impact the peripheral neuropathic pain market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the peripheral neuropathic pain market in the 7MM. However several factors may impede the growth of the peripheral neuropathic pain market. The management of DPN is challenging due to the persistent and severe nature of neuropathic pain, which is frequently ineffectively treated and negatively impacts the quality of life, further complicated by pharmacogenetic and genetic variations in patients; additionally, while improving glycemic control in Type-2 diabetes remains uncertain, the availability of low-cost generics in the treatment landscape may significantly hamper the uptake of emerging therapies, increasing the burden and associated health costs. Moreover, peripheral neuropathic pain treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, peripheral neuropathic pain market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact peripheral neuropathic pain market growth. Scope of the Peripheral Neuropathic Pain Market Report Therapeutic Assessment: Peripheral Neuropathic Pain current marketed and emerging therapies Peripheral Neuropathic Pain Market Dynamics: Key Market Forecast Assumptions of Emerging Peripheral Neuropathic Pain Drugs and Market Outlook Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Peripheral Neuropathic Pain Market Access and Reimbursement Download the report to understand which factors are driving peripheral neuropathic pain market trends @ Peripheral Neuropathic Pain Market Trends Table of Contents Related Reports Peripheral Neuropathic Pain Epidemiology Forecast Peripheral Neuropathic Pain Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Peripheral Neuropathic Pain epidemiology trends. Peripheral Neuropathic Pain Pipeline Peripheral Neuropathic Pain Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Peripheral Neuropathic Pain companies, including Haisco Pharmaceutical Group, GlaxoSmithKline, Algiax Pharmaceuticals, Apurano Pharmaceuticals GmbH, Eli Lilly and Company, Shanghai SIMR Biotechnology, Lexicon Pharmaceuticals, among others. Diabetic Neuropathy Market Diabetic Neuropathy Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key diabetic neuropathy companies, including Novo Nordisk, Ionis Pharmaceuticals, Pfizer, Regeneron, NeuroMetrix, among others. Diabetic Neuropathy Pipeline Diabetic Neuropathy Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key diabetic neuropathy companies, including Goldfinch Bio, Novartis, Serodus, CURACLE, Daiichi Sankyo, NeuroBo Pharmaceuticals, Dong-A Pharmaceutical , among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP

Drug ApprovalPhase 2

07 Nov 2016

·www.bioportfolio.com

JP Giants leaning in for becoming a Speciality Global PharmaSakigake designation A Push from government to Innovate!Essential drugs exemption from Z2 rule Balancing long listed pricing pressure!Authorized Generics, Biosimilars, and Patent Litigations Av

Sakigake designation A Push from government to Innovate! Essential drugs exemption from Z2 rule Balancing long listed pricing pressure! Authorized Generics, Biosimilars, and Patent Litigations Avenues to grow in JP Generic market! Increasing decline in long listed products sales, and a few success in R D in the last decade had put JP giants under pressure to refocus on Innovation with specialty therapy area to strengthen their global presence. Eisai Ajinomoto JV, TevaTakeda partnership for Speciality Generics is the actions in this direction. Fast track approval based on Sakigake designation is the step by PMDA/MHLW to encourage JP Pharmas to research in the area of high unmet medical need/orphan disease where US biotech has taken a successful leap in last decade. In innovation space, Nivolumab, Alectinib, Dolutegravir global success again demonstrate ability of JP pharma/university research house to contribute Pharma Innovation, while encouraging regulatory environment for Regenerative Medicine Drug Development and Drug Repurposing will make Japan front runner in this space. From late stage pipeline/new launch, Mirogabalin approval in Neuropathic Pain, Brintellix Cognition label expansion, Edoxaban uptake in EU, Alectinib uptake in US and ACE910 approval for hemophilia will decide Japanese Innovator growth in Global market. The biennial price cut scheduled in April2016 will balance Innovation premium with long listed price cut Z2 rule to increase R D productivity. In next 3 years, 950b drugs will go off patent in Japan and as happened in 2015, substantial volume growth due to new patent expiry opportunities will help Japanese generic companies to withstand NHI pricing pressure. Consolidation activities like TevaTakeda JV will make this growing domestic generic market more competitive and companies with direct sales model may fetch upper hand due to less dependence on wholesale distribution channel. Challenging Alimta patent and Evista patent against Lilly in Japan, and Livalo ANDA filing in US by JP Generic companies is indicative of the changing breadth of the JP generic giants from launching generics in Japan to becoming a patent challenger Intellectual property rights challenging generic company. This is a step towards finding its place against the world generic players in the coming time. Successful launch of Blopress AG, Plavix AG in last few years stamps Authorized Generics as one of the attractive opportunity for Generic players in Japan. Encouraging Uptake of Filgrastim BS and Lantus BS in Japan is indicative of Japan to be the next important market after EU in the next five years for growth of Biosimilar players. In contrast, there is a very slow uptake post launch of Remicade biosimilar 1% volume share. In this report we analyzed therapy focus, changing Strategies, pipeline and key growth drivers of 12 major Japanese biopharma companies Pure play innovators/ Innovators+ Generics/Pure play generics and detailed our view on their strategic action to withstand in domestic market and expand globally with their interest for inlicensing external innovation from the globe for increasing RD productivity and priorities on M A side.

Generic DrugBiosimilarFast Track

100 Deals associated with Mirogabalin Besilate

External Link

KEGG	Wiki	ATC	Drug Bank
-	Mirogabalin Besilate	N	DB11825

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetic peripheral neuropathic pain	CN	Daiichi Sankyo Co., Ltd.	28 Jun 2024
Neuralgia	JP	Daiichi Sankyo Co., Ltd.	08 Jan 2019

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pain	Preclinical	DE	Daiichi Sankyo, Inc.	27 Oct 2014
Pain	Preclinical	FI	Daiichi Sankyo, Inc.	27 Oct 2014
Pain	Preclinical	RS	Daiichi Sankyo, Inc.	27 Oct 2014
Pain	Preclinical	NL	Daiichi Sankyo, Inc.	27 Oct 2014
Pain	Preclinical	SE	Daiichi Sankyo, Inc.	27 Oct 2014
Pain	Preclinical	NO	Daiichi Sankyo, Inc.	27 Oct 2014
Pain	Preclinical	CA	Daiichi Sankyo, Inc.	27 Oct 2014
Pain	Preclinical	CZ	Daiichi Sankyo, Inc.	27 Oct 2014
Pain	Preclinical	FR	Daiichi Sankyo, Inc.	27 Oct 2014
Pain	Preclinical	DK	Daiichi Sankyo, Inc.	27 Oct 2014

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03901352 (CTgov)	Phase 3	Neuralgia	300	Mirogabalin (Mirogabalin)	nxkwpmsdaj(sklfwmaabp) = tfhqberbcu ffykaillzu (iksgryewaa, ncwotwhnys - uginouegkb) View more	-	23 Sep 2024
				Placebo (Placebo)	nxkwpmsdaj(sklfwmaabp) = fcizlmspkn ffykaillzu (iksgryewaa, sutajsecsr - sonofleylf) View more
Pubmed	Phase 3	Neuralgia	-	Mirogabalin	(cqsqawnlxe): odds ratio = 1.91 (95% CI, 1.11 - 3.27)	Positive	14 Dec 2022
				Placebo
NCT02318719 \| NCT02318706 (Pubmed \| Clin Ther)	Phase 3	Neuralgia	1,587	Placebo	(ugmubzenor) = hrxicnimry mwsxaycxrz (rjdmfcpive ) View more	-	28 May 2021
				Mirogabalin 15-mg once daily	(ugmubzenor) = atpvuklidg mwsxaycxrz (rjdmfcpive ) View more
NCT01496365 (CTgov)	Phase 2	Neuralgia \| Diabetic peripheral neuropathy	452	placebo (Placebo)	ntwyjpuifj(yqyeyuuphn) = qnotrmnaug rymvjydvzj (ccvedkcbtn, bkisomgoge - ubrjujycme) View more	-	05 Jan 2021
				Pregabalin (Pregabalin 150 mg BID)	ntwyjpuifj(yqyeyuuphn) = fzdtuaxtcv rymvjydvzj (ccvedkcbtn, dzpuqqcqro - jrdxuiybuh) View more
NCT02146430 (CTgov)	Phase 3	Pain \| Fibromyalgia	1,293	Placebo capsule (Placebo)	ocmrfdfvkn(dmyhlzibbb) = wzftfbrtsd ypbjbhmobx (mtduawzncr, pycbjayvav - nkjfilenip) View more	-	09 Nov 2020
				Placebo tablet+Pregabalin (Pregabalin)	mgxklgjkev(qckoutkjxu) = bkbzjsozsw xajcpamaun (bsiivafrkt, svypgrcvhl - qvnvwvxcsi) View more
NCT02187159 (CTgov)	Phase 3	Pain \| Fibromyalgia	1,270	Placebo capsule	ggeoeezryf(uwxyznogbr) = bnkeujckui ogamxalecy (juvbvkxdip, vtjipkrtjx - zigjnaxljs) View more	-	09 Nov 2020
NCT02187471 (CTgov)	Phase 3	Pain \| Fibromyalgia	1,301	Placebo capsule (Placebo)	gzttrhxkpx(mqzmabwfey) = qafdsoahyo seoxeefyoz (jkokgeiszg, whxhhkcfoh - xgfidrdjdo) View more	-	09 Nov 2020
				Placebo capsule+DS-5565 (DS-5565 15 mg QD)	gzttrhxkpx(mqzmabwfey) = xzdpnmiyre seoxeefyoz (jkokgeiszg, mrsjrdkxpt - jhxlfmlcsf) View more
NCT02318706 (CTgov)	Phase 3	Diabetic peripheral neuropathic pain	854	placebo	zsbucupoem(nugenhptfx) = zbxebnpexe gpowsdexuz (uyikrdroqg, mkbjaovsgn - eybouohfnb) View more	-	02 Nov 2020
NCT02607280 (CTgov)	Phase 3	Neuralgia, Postherpetic \| Diabetic peripheral neuropathy \| Diabetic peripheral neuropathic pain	35	DS-5565 (Moderate Renal Impairment)	jdipoqsaxh(okeassgxgn) = eaugebixph tqqkfgrlze (oucrtvrtiq, jhhatnxjku - yhkirkyjrl) View more	-	26 Oct 2020
				DS-5565 (Severe Renal Impairment)	jdipoqsaxh(okeassgxgn) = lwvhzdvyuo tqqkfgrlze (oucrtvrtiq, unwaogemjg - vhlkbyctcd) View more
NCT02496884 (CTgov)	Phase 3	Pain \| Fibromyalgia \| Chronic Kidney Diseases	56	Placebo (M-CKD Placebo)	qbnogxqnqm(xgwcxkbupz) = amjoqecqui ekigxdbdnh (wyouphilxi, fyfscflbkn - taexclpkcm) View more	-	12 Oct 2020
				DS-5565 (M-CKD DS-5565 7.5 mg BID)	qbnogxqnqm(xgwcxkbupz) = kdaqbahoco ekigxdbdnh (wyouphilxi, iijqaqkiwp - deimwimciu) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis